Olanzapine crystal modification

Details Olanzapine crystal modification Olanzapine crystal modification

2001-12-19

2004-05-25

Coleman, Brenda (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Unsubstituted hydrocarbyl chain between the ring and the -c-...

Reexamination Certificate

active

06740753

ABSTRACT:

SUMMARY
This invention relates to a novel crystal form of the pharmaceutical compound olanzapine, a process for its preparation and pharmaceutical formulations thereof.
BACKGROUND
The compound 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno{2,3-b}{1,5}benzodiazepine been named according to the U.S.A.N. as olanzapine. It is known as an anti-psychotic agent. The present invention relates to a novel olanzapine crystal modification, hereinafter designated as Form X, which is distinguished from previously known crystal forms by physical and spectroscopic properties such as melting point and powder x-ray diffraction pattern.


REFERENCES:
patent: 5229382 (1993-07-01), Chakrabarti et al.
patent: 5631250 (1997-05-01), Bunnell et al.
patent: 5736541 (1998-04-01), Bunnell et al.
patent: 6020487 (2000-02-01), Bunnell et al.
patent: 733 367 (1996-09-01), None
patent: 0 733 635 (1996-09-01), None
patent: 830 858 (1998-03-01), None
patent: 831 097 (1998-03-01), None

Affiliated with

Also associated with

Rating

Olanzapine crystal modification does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Olanzapine crystal modification, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Olanzapine crystal modification will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3262718